Skip to content

Biological characteristics of sensitization in patients with MIRI

Biological characteristics of sensitization in patients with MIRI

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400088845
Enrollment
Unknown
Registered
2024-08-27
Start date
2024-08-31
Completion date
Unknown
Last updated
2024-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial ischemia reperfusion injury

Interventions

Morphological sensitization group:palpate each seeking areas to confirm whether there are alterations in the skin such as depression, protrusion, subcutaneous nodules, and strips
Pain sensitization group:press each seeking areas with same force to confirm whether there are painful points, and use PAIN TESTTM FPX to test the pain pressure threshold of each painful point
Heat sensitization group:use Infrared thermal camera (Fotric 228s) to detect the heat emission from each seeking region
Conductive sensitization group:use the acupoint resistance measurement system to detect the resistance variation on the skin

Sponsors

Shaanxi University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: MIRI patients: (1) meeting the diagnostic criteria of non-ST elevation acute coronary syndrome in 2023 ESC Guidelines for the management of acute coronary syndromes. (2) received percutaneous coronary intervention within a week. (3) aged 18 to 85 years. (4) willing to participate in this study, and sign on informed consent. Healthy subjects: (1) received a health examination within a week, and confirmed to be in good health. (2) aged 18 to 85 years. (3) willing to participate in this study, and sign on informed consent.

Exclusion criteria

Exclusion criteria: (1) diagnosed as ST-elevation myocardial infarction, with persistent ST-segment elevation or ST-segment elevation equivalents on electrocardiogram. (2) combined with disorders of rhythm, disorders of the heart, muscles, valves, and pericardium, and peripheral vascular disease. (3) suffering from neoplastic disorders, hematopoietic disorders, disorders of hemostasis, infectious diseases, immune-mediated, inflammatory, and rheumatologic disorders. (4) combined with fever. (5) suffering from psychiatric disorders, and unable to cooperate. (6) participating in any other study within 3 months.

Design outcomes

Primary

MeasureTime frame
mRNA;

Countries

China

Contacts

Public ContactHaifa Qiao

Shaanxi University of Chinese Medicine

1511006@sntcm.edu.cn+86 182 2004 6518

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026